Clinical trial
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica…
NCT02200770 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT02200770 |
|---|---|
| Title | N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders |
| Official title | A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders. |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders |
| Intervention type | Drug, Other |
| Interventions | Inebilizumab, Placebo |
| Enrollment | 231 |
| Start date | Apr 1, 2015 |
| Primary completion | Oct 26, 2018 |
| Completion | Nov 6, 2020 |
| First posted | Jul 25, 2014 |
| Last update posted | Dec 3, 2021 |
| Countries | Australia, Bulgaria, Canada, Colombia, Czechia, Estonia, Germany, Hong Kong, Hungary, Israel, Japan, Mexico and 13 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: